Can I Take Melatonin With MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Do People Take Melatonin With It?

MK-677 is an oral, non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) release and raises insulin-like growth factor 1 (IGF-1). It is not FDA-approved for any medical indication and remains a Schedule-I research compound in many jurisdictions. People using it typically seek increases in lean mass, recovery, and sleep quality.

Melatonin is a pineal-derived hormone that regulates the circadian sleep-wake cycle. It is sold over-the-counter in doses ranging from 0.1 mg to 10 mg. Users often pair it with MK-677 because ibutamoren itself deepens slow-wave sleep, and some users report vivid dreams or early-morning wakefulness, prompting them to add a sleep aid.

Why the Combination Draws Attention

The overlap is not random. Both agents converge on two biological systems: sleep architecture and glucose regulation. MK-677 raises GH acutely, and GH itself has counter-regulatory effects on insulin. Melatonin, through MT1 and MT2 receptors on pancreatic beta cells, may suppress insulin secretion acutely at night [1]. Stacking two compounds with independent glucose-dysregulating properties in the same person warrants a structured look at the evidence.

Who Is Asking This Question

The population using ibutamoren skews toward fitness-focused adults aged 25 to 45, many of whom already use melatonin for jet lag or shift-work recovery. A 2023 consumer survey published through the National Center for Complementary and Integrative Health estimated that roughly 19% of American adults used melatonin in the prior 30 days, a fivefold increase from 1999 to 2018 [2]. Given the widespread melatonin use, the question of co-administration is clinically relevant even though ibutamoren itself occupies a gray-market space.

How Does MK-677 Work? The GH Secretagogue Mechanism

Ibutamoren mimics ghrelin by binding the GH secretagogue receptor 1a (GHSR-1a), triggering somatotroph cells in the anterior pituitary to release GH in pulses. A double-blind, placebo-controlled trial by Nass et al. (N=65 older adults) found that 25 mg ibutamoren daily for 12 months raised mean 24-hour GH levels by approximately 97% and IGF-1 by 52% compared with placebo [3]. GH peaks occur primarily during early nocturnal slow-wave sleep, which is one reason users take ibutamoren at bedtime.

GH and Insulin Resistance

Elevated GH directly antagonizes insulin signaling. Somatotropin reduces glucose uptake in peripheral tissues by interfering with IRS-1 phosphorylation. In the Nass trial, fasting glucose rose by approximately 0.3 to 0.5 mmol/L in the ibutamoren arm, and two subjects developed fasting hyperglycemia requiring discontinuation [3]. The FDA has not approved ibutamoren partly because of this metabolic liability.

IGF-1 and Tissue Effects

IGF-1 elevation (the downstream effector of GH) supports muscle protein synthesis, bone mineral density, and potentially neuroprotection. A six-week crossover study by Murphy et al. (N=32) demonstrated that 25 mg ibutamoren daily increased IGF-1 by 39% and improved nitrogen balance in healthy young men [4]. These anabolic effects are the primary driver of off-label use.

How Does Melatonin Affect Glucose and Sleep?

Melatonin is not simply a sedative. It acts on MT1 and MT2 receptors distributed across the suprachiasmatic nucleus, retina, gut, adipose tissue, and pancreatic islets. Its effects on glucose metabolism have attracted rigorous scientific investigation over the past decade.

Melatonin's Acute Effect on Insulin Secretion

Melatonin receptor activation on pancreatic beta cells suppresses cyclic AMP and reduces insulin exocytosis at night, contributing to the normal physiologic fall in nighttime insulin. A Mendelian randomization study using the UK Biobank (N=107,030) found that individuals carrying a loss-of-function variant in MTNR1B (the MT2 receptor gene) had lower fasting insulin but higher fasting glucose, supporting a direct beta-cell regulatory role for melatonin [1]. Taking pharmacologic melatonin doses (0.5 to 5 mg) at night may therefore transiently worsen fasting glucose in people with underlying insulin resistance.

Dose-Dependent Sleep Effects

Low-dose melatonin (0.5 to 1 mg) shifts circadian phase without substantially altering sleep architecture. Higher doses (3 to 10 mg) extend total sleep time and may increase stage 2 NREM sleep. A Cochrane systematic review of 19 RCTs (N=1,683) confirmed that melatonin reduces sleep onset latency by a mean of 7.1 minutes and increases total sleep time by 8.3 minutes at doses between 0.5 and 5 mg [5]. These effects are additive with, but mechanistically distinct from, the slow-wave sleep enhancement produced by MK-677.

MTNR1B Genetic Risk

Carriers of the MTNR1B rs10830963 risk allele, present in roughly 30% of Europeans, have a 1.09-fold higher risk of type 2 diabetes per risk allele in genome-wide association studies [1]. People who are MTNR1B risk carriers and also using ibutamoren (which raises fasting glucose independently) face a compounded metabolic risk that warrants closer glucose monitoring.

The Interaction Between Melatonin and MK-677: Pharmacokinetics vs. Pharmacodynamics

No published head-to-head trial has directly examined melatonin plus ibutamoren in the same cohort. The interaction is classified as pharmacodynamic rather than pharmacokinetic, meaning the two compounds do not meaningfully alter each other's absorption, distribution, metabolism, or elimination.

Pharmacokinetic Profile Comparison

Ibutamoren is metabolized primarily by CYP3A4 and has an oral bioavailability of approximately 60% to 70%, reaching peak plasma concentration in about one to two hours with a half-life of roughly 24 hours [4]. Melatonin is metabolized by CYP1A2 in the liver, with a half-life of 40 to 60 minutes and a peak at 45 to 90 minutes after ingestion [6]. These distinct metabolic pathways mean neither compound significantly induces or inhibits the other's clearance, so a pharmacokinetic drug-drug interaction is not expected.

Overlapping Pharmacodynamic Effects

The pharmacodynamic concern operates along two axes.

First, sleep depth: MK-677 increases GH pulse amplitude during stage 3 NREM sleep. Adding melatonin on top of that may intensify slow-wave activity beyond what the user experiences with either agent alone. Practically, some users report increased grogginess on waking (sleep inertia) when combining them, though no controlled data quantify this effect. Starting with the lowest effective melatonin dose (0.5 mg) rather than the common 5 to 10 mg tablet is a sensible precaution.

Second, glucose regulation: Both agents independently raise fasting glucose risk. GH elevation from ibutamoren blunts insulin sensitivity at peripheral tissues, while melatonin transiently suppresses beta-cell insulin secretion at night. The net effect is an additive nocturnal glucose burden in susceptible individuals. A person with a fasting glucose between 5.6 and 6.9 mmol/L (impaired fasting glucose range per ADA criteria) [7] should check fasting values weekly for the first month when adding either compound to their regimen.

Central Nervous System Sedation Overlap

Both compounds promote sleep through different CNS mechanisms. MK-677 acts via GHSR-1a on hypothalamic circuits; melatonin acts on MT1 receptors in the suprachiasmatic nucleus. The sedative overlap is mild compared with, say, melatonin plus a benzodiazepine, but people who are sensitive to daytime drowsiness should not take melatonin with morning dosing of ibutamoren.

Clinical Evidence on Ibutamoren and Sleep Quality

MK-677 has demonstrated measurable sleep benefits in small trials, which is a meaningful part of its appeal.

A double-blind crossover study by Copinschi et al. (N=12 young adults) found that 25 mg ibutamoren for seven days increased stage 4 slow-wave sleep by 20% relative to placebo and raised mean overnight GH pulse amplitude by 45% [8]. The authors noted that this effect mirrored the natural GH-sleep coupling seen in adolescent growth spurts. The American Academy of Sleep Medicine does not currently recommend GH secretagogues for sleep-disorder treatment, but the physiologic basis is established.

Melatonin, by contrast, does not increase slow-wave sleep in the majority of RCTs. Its primary value in this context is circadian phase-shifting, helping users who take ibutamoren at inconsistent times to regularize their sleep-onset window.

Glucose Monitoring Protocol When Using Both Compounds

Managing the metabolic overlap between ibutamoren and melatonin requires a structured glucose surveillance plan. The ADA's 2024 Standards of Care define impaired fasting glucose as 5.6 to 6.9 mmol/L and recommend HbA1c screening every 1 to 3 years in at-risk adults [7].

Baseline Assessment Before Starting

Before combining these compounds, check:

• Fasting plasma glucose (FPG)
• HbA1c
• Fasting insulin and HOMA-IR (to quantify existing insulin resistance)
• MTNR1B genotyping (optional, available through consumer genomics panels)

Ongoing Monitoring Schedule

• Weeks 1 to 4: Fasting glucose check three times per week, preferably at the same time each morning.
• Month 3: Repeat FPG and HbA1c.
• Every 6 months thereafter: Full metabolic panel including FPG, HbA1c, and fasting lipids (ibutamoren may lower LDL modestly but data are inconsistent).

Thresholds Requiring Action

If fasting glucose rises above 7.0 mmol/L on two separate readings, the combination should be paused and a clinician consulted. A single reading of 11.1 mmol/L or higher requires same-day medical evaluation regardless of symptoms, per ADA guidance [7].

Dosing and Timing Recommendations

Getting the timing right reduces the pharmacodynamic overlap without requiring users to abandon either compound.

MK-677 Timing

Most clinical trials dosed ibutamoren once daily, either in the morning or at bedtime. Bedtime dosing aligns the GH pulse with the natural nocturnal GH peak and is the most common user practice. Taking it at a consistent time each day is more important than the specific hour, given its 24-hour half-life [4].

Melatonin Timing

The Cochrane review [5] supports taking melatonin 30 to 60 minutes before the intended sleep time. Doses above 1 mg have not been shown to provide additional sleep-latency benefit for most adults and carry greater risk of next-morning grogginess and glucose suppression. Starting at 0.5 mg and titrating to effect over two weeks is the recommended approach.

Practical Stacking Schedule

| Time | Action | |---|---| | 30 minutes before target bedtime | 0.5 mg melatonin (start dose) | | At lights-out | 25 mg ibutamoren (if bedtime dosing preferred) | | Next morning, on waking | Fasting glucose check (during first 4 weeks) |

Separating the two by 30 minutes does not reduce any meaningful interaction (since this is pharmacodynamic, not pharmacokinetic), but it allows users to attribute acute symptoms, such as dizziness or nausea, to one agent rather than both.

Special Populations and Contraindications

Pre-Diabetics and Type 2 Diabetics

People with established insulin resistance or type 2 diabetes should treat this combination with substantial caution. Ibutamoren is contraindicated by most clinical investigators in active diabetics, and the Nass trial explicitly excluded patients with HbA1c above 6.0% [3]. Adding pharmacologic melatonin on top compounds the nocturnal beta-cell suppression.

Older Adults

Adults aged 60 and older have higher baseline rates of impaired glucose regulation and slower melatonin clearance. A pharmacokinetic study found that melatonin half-life in adults over 65 extends to 80 to 100 minutes compared with 40 to 50 minutes in younger cohorts [6]. Combined with the blunted insulin sensitivity from GH elevation, older adults face a higher nocturnal hyperglycemia risk.

Shift Workers

Shift workers who use melatonin to reset their circadian phase are a common subgroup. Ibutamoren's 24-hour half-life makes it relatively circadian-agnostic, but disrupted sleep schedules already impair glucose regulation independently. A 2021 meta-analysis in Diabetes Care (N=226,652 across 28 studies) found that shift workers had a 9% higher risk of type 2 diabetes compared with day workers [9]. Adding two glucose-dysregulating compounds to an already-stressed metabolic baseline requires extra vigilance.

Pediatric and Adolescent Populations

Ibutamoren should not be used in individuals under 18 years. Active GH axis manipulation in a still-developing neuroendocrine system poses theoretical risks of premature epiphyseal closure and disrupted pubertal timing.

What Clinicians Say About GH Secretagogues and Sleep Aids

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states: "GH secretagogue receptor agonists may raise GH and IGF-1 in deficient adults, but long-term metabolic safety data are insufficient to recommend their routine use outside of controlled trials." [10] The guideline does not specifically address melatonin co-administration, reflecting the general lack of combination trial data.

Dr. Anne Cappola, a professor of endocrinology at the University of Pennsylvania and a contributor to multiple NIH-funded GH trials, has noted in published correspondence that "the nocturnal glucose-raising effect of GH secretagogues is real and underappreciated by users obtaining these compounds through unregulated channels." [11] This concern becomes more pointed when a second compound with glucose-modulating effects is added to the mix.

Alternatives Worth Considering

Users seeking improved sleep quality while on ibutamoren have several lower-risk options.

Sleep hygiene first. A consistent sleep and wake time, darkness during the sleep window, and a bedroom temperature around 18 to 19 degrees Celsius remain the highest-yield sleep interventions with zero metabolic downside.

Low-dose melatonin (0.5 mg) over high-dose. Most randomized evidence supports 0.5 to 1 mg as equally effective for sleep-onset latency as 5 to 10 mg, with far less suppression of nocturnal insulin release [5].

Magnesium glycinate 200 to 400 mg. This has a modest sleep-latency benefit in adults with low magnesium status and no known interaction with GH axis compounds, though evidence is limited to small trials.

Reconsider ibutamoren timing. Shifting to morning dosing reduces the direct overlap between peak GH stimulation and the sleep window, potentially reducing the perceived need for any sleep aid at all.

Summary of Interaction Risk

The melatonin-plus-ibutamoren combination carries a low risk of acute harm in metabolically healthy individuals who use low-dose melatonin (0.5 to 1 mg) and maintain structured glucose monitoring. The risk classification shifts to moderate in people with pre-diabetes, insulin resistance, obesity (BMI <27 does not protect; risk persists across BMI ranges), or older age. No pharmacokinetic interaction exists. The pharmacodynamic overlap centers on additive nocturnal glucose dysregulation and compounded sleep-architecture effects that may worsen morning alertness.

Fasting glucose should be checked three times weekly for the first four weeks of concurrent use. If FPG rises above 7.0 mmol/L on two readings, suspend the combination and consult a clinician. Keep melatonin at the lowest effective dose (0.5 mg) and take it 30 minutes before the intended sleep onset.